Cellectis acquires assets from Cyto Pulse Sciences Inc.
“Cyto Pulse’s assets are a great strategic fit for Cellectis,” said André Choulika, Chief Executive Officer of Cellectis. “As we announced last year, part of our development strategy is to acquire businesses that complement our existing meganuclease platform and that can be leveraged across all aspects of our business, from research to therapeutics. We saw such an opportunity in the technologies at Cyto Pulse Sciences Inc. and look forward to unlocking the value of these assets.”
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.